Stratatech Engineers Skin Substitute With Potent Anti-Infective Function
Stratatech Corp., a privately-held regenerative medicine company, announced that it has genetically modified its StrataGraft® living human skin substitute to actively fight costly bacterial infections that routinely develop at the site of burns and other severe skin injuries, such as skin ulcers. Bacterial infection is a primary cause of skin graft rejection and can significantly increase the hospital costs of burn and other skin injury patients. Stratatech’s skin-substitute innovation, detailed in an article published online this morning by the journal Molecular Therapy, enables the immediate topical delivery of a potent anti-infective that actively inhibits bacterial growth and promotes regrowth of the patient’s own cells.
Stratatech’s genetically-engineered skin substitute was generated using a non-viral vector, or carrier. The company believes it is the first time a virus-free approach has been used to genetically modify a living, cell-based tissue substitute. The data published in Molecular Therapy demonstrate that the modified tissue contained 139-fold more anti-infective proteins called host defense peptides than unmodified tissue in vitro.
![How can I Remove Wrinkles Under Eyes? Reblog this post [with Zemanta]](http://img.zemanta.com/reblog_e.png?x-id=a06997f3-b4d6-4b66-aa50-84fe8d93093a)